Therapeutic potential of A₂ and A₃ adenosine receptor: a review of novel patented ligands

Bibliography

• Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010;316:1284-8
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Ijzerman AP, Jacobson KA, International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64
   PubMed Web of Science ®Google Scholar
• Trincavelli ML, Daniele S, Martini C. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 2010;10:860-77
   PubMedGoogle Scholar
• Ciruela F, Albergaria C, Soriano A, Adenosine receptors interacting proteins (ARIPs): behind the biology of adenosine signaling. Biochim Biophys Acta 2010;1798:9-20
   Web of Science ®Google Scholar
• Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors. TiPS 1996;17:364-72
   PubMed Web of Science ®Google Scholar
• Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. TiPS 1997;18:338-44
   PubMed Web of Science ®Google Scholar
• Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008;108:238-63
   PubMed Web of Science ®Google Scholar
• Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep–wake regulation. Prog Neurobiol 2004;73:379-96
   PubMed Web of Science ®Google Scholar
• Mustafa SJ, Morrison RR, Teng B, Pelleg M. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 2009;193:161-88
   Google Scholar
• Shryock JC, Snowdy S, Baraldi PG, A2A adenosine receptor reserve for coronary vasodilation. Circulation 1998;98:711-18
   PubMed Web of Science ®Google Scholar
• Valls MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 2009;77:1117-24
   PubMed Web of Science ®Google Scholar
• Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153:S446-56
   PubMed Web of Science ®Google Scholar
• Fozard JR, Ellis KM, Villela Dantas MF, Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002;438:183-8
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Sacchetto V, Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808:1400-12
   Web of Science ®Google Scholar
• Adenosine Therapeutics, LLC. Agonists of A2A adenosine receptors for treating recurrent tumor growth in the liver following resection. WO130902; 2008
   Google Scholar
• Cronstein BN, Peng ZS. Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening. US0123510; 2009
   Google Scholar
• Guerrant RL, Linden JM, Warren CA, Methods of treating enteritis, intestinal damage, and diarrhea from C. difficile with an A2A adenosine receptor agonist. WO124150; 2008
   Google Scholar
• Rieger JM, Linden JM, Macdonald TL, 2-Polycyclic propynyl adenosine analogs having A2A agonist activity. US7875595; 2011
   Google Scholar
• Rieger JM, Linden JM, Macdonald TL, 2-Polycyclic propynyl adenosine analogs having A2A agonist activity. US7442687; 2008
   Google Scholar
• PGX-Health, LLC. Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2A agonists. WO002917; 2011
   Google Scholar
• CV Therapeutics, Inc. Use of A2A adenosine receptor agonists in the treatment of ischemia. WO063712; 2008
   Google Scholar
• Novartis AG. Adenosine derivatives as A2A receptor agonists. WO031875; 2008
   Google Scholar
• Novartis AG. Bisadenosine compounds as adenosine A2A receptor agonists. EP2018388; 2011
   Google Scholar
• Biovitrum AB. Therapeutic compounds. WO000743; 2008
   Google Scholar
• Biovitrum AB. Therapeutic compounds. WO000744; 2008
   Google Scholar
• Muller C. Phosphorylated A2A receptor agonists. WO107598; 2007
   Google Scholar
• Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Red Rev 2006;26:131-59
   PubMedGoogle Scholar
• Kyowa Hakko Kirin Co., Ltd. Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients. NLM Identifier: NCT00957203. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-. Available from: http://clinicaltrials.gov/ct2/show/NCT00957203 [Last accessed 9 January 2012]
   Google Scholar
• Schwarz Pharma, AG. 8-Ethinyl xanthine derivatives as selective A2A receptor antagonists. EP1939197; 2008
   Google Scholar
• Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists. WO116185; 2008
   Google Scholar
• Vernalis R&D, Ltd. Pyrimidine compounds as purine receptor antagonist. US7875600; 2011
   Google Scholar
• Palobiofarma, SL. 4-Aminopyrimidine derivatives and their adenosine A2A receptor antagonists. WO121418; 2011
   Google Scholar
• Adenosine Therapeutics, LLC. Selective antagonists of A2A adenosine receptors. US0176858; 2008
   Google Scholar
• Sigma-Tau Industrie Farmaceutiche Riunite SpA. Oxidated derivatives of triazolypurines useful as ligands for the adenosine A2A receptor and their use as medicaments. WO106145; 2010
   Google Scholar
• Vernalis R&D, Ltd. Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists. US7405219; 2008
   Google Scholar
• Vernalis R&D, Ltd. Pyrrolo[2,3-d]pyrimidine and their use as purinergic adenosine antagonists. US7598246; 2009
   Google Scholar
• Domain Therapeutics. New adenosine receptor ligands and uses thereof. WO084425; 2010
   Google Scholar
• CV Therapeutics, Inc. A2A adenosine receptor antagonists. WO070529; 2008
   Google Scholar
• Johnson & Johnson. Methylene amines of thieno[2,3-d]pyrimidine and their use as adenosine A2A receptor antagonists. US0093702; 2010
   Google Scholar
• Johnson & Johnson. Amides of thieno[2,3-d]pyrimidine and their use as adenosine A2A receptor antagonists. US0093714; 2010
   Google Scholar
• Johnson & Johnson. Phenyl and heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine A2A receptor antagonists. US0093721; 2010
   Google Scholar
• Johnson & Johnson. Heteroaryl and phenyl substituted thieno[2,3-d]pyrimidine as adenosine A2A receptor antagonists. US0093722; 2010
   Google Scholar
• Harris JM, Neustadt BR, Liu H, Amino-quinoxline and amino-quinoline compounds for use as adenosine A2A receptor antagonists. US0105513; 2011
   Google Scholar
• Schering Corp. Adenosine A2A receptor antagonists. WO002596; 2008
   Google Scholar
• Hodgson RA, Bertorelli R, Varty GB, Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009;330:294-03
   PubMed Web of Science ®Google Scholar
• Schering Corp. 1,2,4-Triazolo[4,3-c]pyrimidin-3-ones and pyrazolo[4,3-e] 1,2,4-triazolo[4,3-c]pyrimidin-3-ones compounds for use as adenosine A2A receptor antagonists. US0152256; 2011
   Google Scholar
• King Pharmaceuticals, Inc. Adenosine A2A receptor antagonists. US0242672; 2008
   Google Scholar
• Janssen Pharmaceuticals. Arylindenopyrimidines compounds and use as an adenosine A2A receptor antagonists. WO055308; 2009
   Google Scholar
• Janssen Pharmaceuticals. Arylindenopyrimidines and their use as adenosine A2A. WO055548; 2009
   Google Scholar
• Janssen Pharmaceuticals. Heterocyclyl substituted arylindenopyrimidines and their use as highly selective adenosine A2A receptor antagonists. WO053510; 2011
   Google Scholar
• Hoffman B, Chang H, Dall'Aglio E, Reaven GM. Desensitization of adenosine receptor-mediated inhibition of lipolysis. J Clin Invest 1986;78:185-90
   PubMed Web of Science ®Google Scholar
• Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005;67:1385-7
   PubMed Web of Science ®Google Scholar
• Merighi S, Mirandola P, Varani K, A glance at adenosine receptors: novel target for antitumor therapy. Pharm Ther 2003;100:31-48
   PubMed Web of Science ®Google Scholar
• Harada H, Asano O, Hoshino Y, 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J Med Chem 2001;44:170-9
   PubMed Web of Science ®Google Scholar
• Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive disease. Trends Pharmacol Sci 2009;30:528-35
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dai Y, Wen J, Detrimental effects of adenosine signalling in sickle cell disease. Nat Med 2011;17:79-87
   PubMed Web of Science ®Google Scholar
• King Pharmaceuticals, Inc. Adenosine A2B receptor agonists. US7691825; 2010
   Google Scholar
• Bayer Healthcare AG. Use of substituted–thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion damage. WO099958; 2006
   Google Scholar
• Gilead Sciences, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists. US0184002; 2011
   Google Scholar
• Gilead Sciences, Inc. Prodrugs of A2B adenosine receptor antagonists. US0160162; 2011
   Google Scholar
• Leung E. Methods of treating atherosclerosis. US0118276; 2011
   Google Scholar
• Thompson RD. Substituted 8-[6-amino-3-pyridyl]xanthines. US7875608; 2011
   Google Scholar
• PGX-Health, LLC. Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine A2B antagonists. WO005871; 2011
   Google Scholar
• Novartis, Insitutes for biomedical Research, Inc. Thiazole derivatives as A2B antagonists. US0233938; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. Substituted thiazolo[5,4-d]pyrimidine urea derivatives. US7947692; 2011
   Google Scholar
• Laboratorios Almirall S.A. Imidazopyridine derivatives as A2B receptor antagonists. US7855202; 2010
   Google Scholar
• Adenosine Therapeutics, LLC. Pyrrolo[3,2-d]pyrimidines that are selective antagonists of A2B adenosine receptors. US0082347; 2009
   Google Scholar
• Cheong SL, Federico S, Venkatesan G, The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry and in silico approaches. Med Res Rev 2011 Published on-line
   Google Scholar
• von Lubitz DKJE. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur J Pharmacol 1999;371:85-102
   Google Scholar
• Madi L, Ochaion A, Rath-Wolfson L, The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004;10:4472-9
   PubMed Web of Science ®Google Scholar
• Madi L, Bar-Yehuda S, Barer F, A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278:42121-30
   PubMed Web of Science ®Google Scholar
• Ohana G, Bar-Yehuda S, Arich A, . Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:1552-8
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Varani K, Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine subtype. J Cell Physiol 2007;211:826-36
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Rainaldi G, Giammarioli AM, The A3 adenosine receptor mediates cell spreading reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 1997;241:297-304
   Google Scholar
• Martin L, Pingle SC, Hallam DM, Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosi factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006;316:71-8
   PubMed Web of Science ®Google Scholar
• La Sala A, Gadina M, Kelsall BL. G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 2005;175:2994-9
   Web of Science ®Google Scholar
• Schlozer-Schrehardt U, Zenkel M, Decking U, Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 2005;46:2023-34
   Google Scholar
• Can-Fite Biopharma Ltd. Use of A3 adenosine receptor agonist in osteoarthritis treatment. WO063538; 2007
   Google Scholar
• Can-Fite Biopharma Ltd. Pharmaceuticals composition comprising A3 adenosine receptor agonist (IB-MECA/CF101) for treatment of psoriasis. WO027348; 2011
   Google Scholar
• Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the treatment of dry eye disorders. WO086044; 2007
   Google Scholar
• Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the reduction of intraocular pressure. WO134067; 2010
   Google Scholar
• Gahl WA, Boehm M, St. Hilaire C, Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders. WO123518; 2011
   Google Scholar
• Ramot at Tel-Aviv University, Ltd. A3 adenosine receptor ligands for modulation of pigmentation. WO010306; 2011
   Google Scholar
• Jacobson KA, Melman A. Purine derivatives as A3 receptor selective agonist. US0046166; 2011
   Google Scholar
• Jacobson KA, Melman A. Methanocarba adenosine derivatives and dendrimer conjugated thereof. WO123881; 2009
   Google Scholar
• Goblyos A, Brussee J, Ijzerman AP, A3 adenosine receptor allosteric modulators. US0054476; 2009
   Google Scholar
• Can-Fite Biopharma Ltd. A3 adenosine receptor allosteric modulators. US0144156; 2010
   Google Scholar
• May LT, Briddon SJ, Hill SJ. Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye brilliant black BN: evidence for allosteric interactions. Mol Pharmacol 2010;77:678-86. 109
   Google Scholar
• Lane JR, Beukers MW, Mulder-Krieger T, IJzerman AP. The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. Biochem Pharmacol 2010;79:48-56
   Google Scholar
• Addex Pharma, SA. Novel heteroaryl derivatives as antagonists of adenosine A3 receptor. WO010871; 2009
   Google Scholar
• CV Therapeutics, Inc. A3 adenosine receptor antagonists. WO052310; 2009
   Google Scholar
• Santaris Pharma, A/S. Adenosine receptors antagonists. US0062994; 2010
   Google Scholar
• FM Therapeutics Co., Ltd. Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient. WO108508; 2008
   Google Scholar
• Avila M, Stone R. Effective delivery of cross-species A3 adenosine receptor antagonist to reduce intraocular pressure. WO045330; 2008
   Google Scholar
• Jacobson KA, Melman A, Wang BBR. A3 adenosine receptor antagonists and partial agonists. US0171130; 2011
   Google Scholar
• Sanofi Aventis. Aminoquinoline derivatives and their use as adenosine A3 ligands. US0112092; 2011
   Google Scholar
• King Pharmaceuticals R&D, Inc. Adenosine A3 modulators. US7470698; 2008
   Google Scholar
• King Pharmaceuticals R&D, Inc. Adenosine A3 receptor modulators. US7435740; 2008
   Google Scholar
• Faust Pharmaceuticals. Pyrrolo[1,2-a]quinoxaline derivatives as adenosine A3 receptor modulators and uses thereof. US0093476; 2009
   Google Scholar